Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT
(firmenpresse) - MONTREAL, QUEBEC -- (Marketwired) -- 05/16/13 -- Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, announced today that the Company has been granted United States Patent No. 8,426,562 covering methods of treating carcinomas with antibodies targeting the region of secreted clusterin (sCLU) responsible for promoting epithelial-to-mesenchymal transition (EMT). Yves Cornellier, President & CEO of Alethia commented, "The issuance of this patent broadens our intellectual property estate for the treatment of solid tumors in which sCLU induces EMT. It represents an important milestone for the Company since this patent confers a broad protection in this field."
Alethia and its collaborators at the National Research Council Canada have demonstrated that sCLU is a potent inducer of EMT, a mechanism that is one of the most important contributors to tumor invasion and metastasis. Dr. Mario Filion, Chief Scientific Officer of Alethia commented, "Antibodies targeting a specific epitope in the carboxy-terminal portion of sCLU inhibit the ability of the protein to induce EMT. The lead monoclonal antibody in this program, AB-16B5, causes an increase in responsiveness of tumors to chemotherapy and reduces the growth and invasion of the tumors. This monoclonal antibody represents one of the few EMT inhibitors for the treatment cancer indications such as prostate, breast and pancreatic cancer."
About Alethia Biotherapeutics Inc.
Alethia is a privately held, Montreal-based biotechnology company created in 2002. Alethia develops monoclonal antibody therapeutics against novel clinically relevant targets identified using its patented STAR discovery technology. Alethia is well funded with top-tier investors committed to the success of the Company notably, Agechem Venture Fund, BDC Capital and GO Capital.
Contacts:
Yves Cornellier
President and CEO
(514) 858-7666 ext. 206
Mario Filion, Ph.D.
Executive VP, CSO
(514) 858-7666 ext.207
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 16.05.2013 - 12:17 Uhr
Sprache: Deutsch
News-ID 260823
Anzahl Zeichen: 0
contact information:
Town:
MONTREAL, QUEBEC
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 190 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT"
steht unter der journalistisch-redaktionellen Verantwortung von
Alethia Biotherapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
